2026-01-29 - Analysis Report
**Lam Research (LRCX) Analysis Report**
=====================================

### Company Overview

Lam Research is a US-based company that specializes in manufacturing semiconductor processing equipment.

### Return Rate Analysis
-------------------------

* Cumulative return of review stock: 954.15%
* Cumulative return of comparison stock (S&P 500, VOO): 128.51%
* Divergence (max: 825.60, min: -6.80, current: 825.60, relative divergence: 100.00%)

The review stock has shown an extremely high return rate compared to the S&P 500, indicating significant investment potential. However, the extremely high divergence suggests that the stock has been highly volatile.

### Alpha, Beta Analysis
-------------------------

| Year       | CAGR | MDD  | Alpha | Beta | Cap(B) |
|------------|------|------|-------|------|-------|
| 2016-2018  | 14.0% | 33.7% | 5.0% | 1.6 | 17.3B |
| 2017-2019  | 89.0% | 33.7% | 64.0% | 1.7 | 37.1B |
| 2018-2020  | 147.0% | 44.4% | 123.0% | 1.5 | 59.9B |
| 2019-2021  | 293.0% | 44.4% | 229.0% | 1.6 | 91.2B |
| 2020-2022  | 2.0% | 54.3% | -3.0% | 1.6 | 53.3B |
| 2021-2023  | 65.0% | 54.3% | 47.0% | 1.8 | 99.3B |
| 2022-2024  | -11.0% | 45.7% | -41.0% | 1.9 | 91.6B |
| 2023-2025  | 482.0% | 46.1% | 406.0% | 2.0 | 217.0B |

The Alpha and Beta values indicate that the stock has shown significant investment potential and high volatility, respectively, across different time periods.

### Recent Stock Price Fluctuations
---------------------------------

* Close: $238.46
* Last-market: {'price': 239.75, 'previousClose': 238.46, 'change': 0.54}
* 5-day SMA: $225.67
* 20-day SMA: $208.24
* 60-day SMA: $175.84

The recent stock price has shown an upward trend, with a slight increase in the past day. The 5-day SMA is above the current price, indicating that the short-term trend may be upward. However, the 20-day and 60-day SMAs are below the current price, indicating that the long-term trend may be downward.

### RSI, PPO Index Indicators
-------------------------------

* Market Risk Indicator (MRI): 0.70
* RSI: 67.75
* PPO: 0.06
* Hybrid Signal: Buy (Cash 0%)
Risk Level: Medium (MRI 0.70)
* Recent (20 days) relative divergence change: 0.00 (0): flat
* 7-day Rank change: 13 (+): rank up
* 7-day Dynamic Expected Return change: 34.30 (+): improving

The MRI and RSI values indicate that the market risk is medium and the stock is overbought. The PPO value is low, indicating a potential buy signal. However, the recent relative divergence change is flat, indicating no significant change in the trend.

### Recent News & Significant Events
--------------------------------------

* [2026-01-28] Why Record Highs For LRCX Stock May Face A Reality Check In 2026 - Forbes
* [2026-01-28] Lam Research (LRCX) Has a Shortage That Can’t Be Met, Says Jim Cramer - Yahoo Finance UK
* [2026-01-28] Can Lam Research Stock Withstand These Pressures? - Trefis
* [2026-01-28] Lam Research stock price pops in premarket as LRCX heads into earnings - TechStock²
* [2026-01-28] Is Lam Research (LRCX) Pricing In Too Much After A Powerful Three Year Rally? - simplywall.st
* [2026-01-28] Live Analysis: Will Lam Research Beat Q2 Earnings? - 24/7 Wall St.

These recent news and events indicate that the stock may face challenges and pressures, but still has the potential to perform well.

### Analyst Opinions
---------------------

* Analyst Consensus:
  - Key: Buy
  - Mean (1=StrongBuy~5=Sell): 1.72 (~Buy)
  - Opinions: 31
  - Target Price (avg/high/low): 216.81 / 265.00 / 115.00

The analyst consensus indicates that the general opinion is to buy the stock, with a target price range of $216.81 to $265.00.

### Recent Earnings Analysis
------------------------------

| Date | EPS | Revenue |
|---|---:|---:|
| 2025-10-24 | 1.24 | 5.32 B$ |
| 2025-04-25 | 1.04 | 4.72 B$ |
| 2025-01-31 | 0.93 | 4.38 B$ |
| 2024-10-28 | 0.86 | 4.17 B$ |
| 2025-10-24 | 0.86 | 4.17 B$ |

The recent earnings have shown a decline in EPS and revenue, indicating a potential downward trend in the stock price.

### Financial Information
-------------------------

**Revenue and Profitability:**

| Quarter | Revenue | Profit Margin |
|---------|----------|---------------|
| 2025-09-30 | $5.32B | 50.43% |
| 2025-06-30 | $5.17B | 50.08% |
| 2025-03-31 | $4.72B | 49.02% |
| 2024-12-31 | $4.38B | 47.37% |
| 2024-09-30 | $4.17B | 48.05% |

**Capital and Profitability:**

| Quarter | Equity | ROE |
|---------|---------|-----|
| 2025-09-30 | $10.19B | 15.39% |
| 2025-06-30 | $9.86B | 17.44% |
| 2025-03-31 | $9.51B | 13.99% |
| 2024-12-31 | $8.81B | 13.52% |
| 2024-09-30 | $8.47B | 13.18% |

The financial information indicates that the revenue has been declining, while the profit margin has been increasing. The capital and profitability information shows that the equity has been increasing, while the ROE has been fluctuating.

### Comprehensive Analysis (Summary of previous items)
---------------------------------------------------

* The review stock has shown an extremely high return rate compared to the S&P 500, indicating significant investment potential.
* The Alpha and Beta values indicate that the stock has shown significant investment potential and high volatility, respectively, across different time periods.
* The recent stock price has shown an upward trend, with a slight increase in the past day.
* The MRI and RSI values indicate that the market risk is medium and the stock is overbought.
* The recent news and events indicate that the stock may face challenges and pressures, but still has the potential to perform well.
* The analyst consensus indicates that the general opinion is to buy the stock, with a target price range of $216.81 to $265.00.
* The recent earnings have shown a decline in EPS and revenue, indicating a potential downward trend in the stock price.
* The financial information indicates that the revenue has been declining, while the profit margin has been increasing.

Overall, the stock has shown significant investment potential, but also faces challenges and pressures. The general opinion is to buy the stock, with a target price range of $216.81 to $265.00. However, the recent earnings and financial information indicate a potential downward trend in the stock price.

**Disclaimer:** This report is for informational purposes only and does not constitute financial advice. Investment involves risk.